Massimo F Piepoli 1, 2 Update on cardiovascular prevention in clinical practice European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regularly updated, most recently in 2016, by the Sixth European Joint Task Force. Given the amount of new information that has become available since then, components from the task force and experts from the European Association of Preventive Cardiology of the European Society of Cardiology were invited to provide a summary and critical review of the most important new studies and evidence since the latest guidelines were published.
The exponential development within the field of technology in assessing novel biomarkers, detailed physiological data and behaviour in large cohorts are fostering knowledge and implementation strategies in preventive cardiology. However, most of the intervention studies on the effects of lifestyle intervention are proof-of-concept studies involving less than 500 patients. Larger intervention trials enrolling more than 1000 individuals or patients, numbers comparable with pharmacological studies in cardiology, are very limited. Thus, there is a clear demand for conducting large international, multi-centre randomized controlled trials including personalized prevention strategies as well as new technology, also focusing on long-term adherence and patient population implementation. The current update of the primary prevention position statement is a call for action.
Health education in both primary and secondary prevention
Health literacy is associated with lower cardiovascular risk and larger adherence to prescribed medications, lower re-admission rate after acute events. 1 However, it has been found that nearly half of all adults in eight European countries show inadequate or problematic health literacy skills. 2 Policy action to address the health literacy crisis should be promoted at all levels.
In keeping with these findings, here Lindahl et al. investigated the association between low health literacy, increased risk for cardiovascular disease in 3459 subjects without known cardiovascular disease. Health education was defined as basic health literacy, i.e. the ability to read and understand written medical information. Low health literacy was found in 20% of the subjects whereas high health literacy was associated with a higher degree of education, measured as the proportion of the group having attained university level education. On the other hand, subjects with low health literacy had a higher proportion of carotid artery plaques as well as higher cardiovascular risk scores, fasting plasma glucose concentration and systolic blood pressure.
Heart School is a program of the Swedish Health Service for patients who presented after acute myocardial infarction to re-educate at a secondary prevention level: it promotes interdisciplinary measures for reducing cardiovascular risk. A study group from Uppsala University analysed the records of over 47,000 patients enrolled in the nationwide heart registry, SWEDEHEART (2006 SWEDEHEART ( -2015 . They found a statistical significance benefit from attending Heart School in reducing events from cardiovascular and overall mortality, indicating that the service performed in the Heart Schools reduces to almost half these rates of mortality. The study still opens up scope for further research related to the theme, such as cost-effectiveness analysis and serial evaluations of follow-up time in Heart Schools. Another open question is how the authors separated the effect of the different interventions implemented in secondary prevention programmes, from the effect generated by the Heart School. In fact, while patient education is part of any comprehensive secondary prevention programme, other important components include risk factor modification, exercise training, psychosocial management and nutritional counselling. 3 
Role of interleukin-6 in atherogenesis and in preventive cardiology practice
There is consensus that inflammation similar to cholesterol needs to be reduced to prevent cardiovascular events adequately. 4 In fact, atherosclerosis is a ubiquitous multifactorial chronic degenerative disease in which pro-atherogenic lipoproteins and inflammation are complementary factors. Among different pathways that regulate inflammation, interleukin-6 (IL-6) and its effector mechanisms play a pivotal role. There is evidence from CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) that inhibition of IL-1b with downstream IL-6 signalling modulation prevents atherosclerotic cardiac events. 5 There is very recent evidence showing that the evaluation of the IL-6 trans-signalling pathway may help discriminate and reclassify cardiovascular risk in middle-aged primary prevention individuals, as shown by Ziegler et al. 6 In this issue of the journal the same authors expand and test their previous findings according to LDL-cholesterol values and the estimated Framingham risk score in 4232 middle-aged Swedish individuals without previous manifestations of cardiovascular disease. They found that the incorporation of an index of intensity of IL-6 trans-signalling to a model including IL-6 levels, which modulates the classic signaling pathway, brings additional discriminatory information to the latter. The study is limited by the fact that IL-6 trans-signalling was determined only once an it needs to be replicated in other populations, also in bigger sample. Finally, the possible elevated costs of the IL-6 trans-signalling determination can be considered as a barrier for its implementation.
Biomarkers for growth prediction of abdominal aortic aneurysm
The clinical management and risk stratification of abdominal aortic aneurysm (AAA), despite its prevalence in the aging population, are still challenging and based only on the estimation of the AAA diameter: however, there is evidence that even small aneurysms can rupture, whereas large aneurysms may remain stable for a long time. In the current issue of the journal, Memon and colleagues present the results of their search for circulating biomarkers of AAA diameter and growth. Among several proteins that were differently concentrated in the plasma of cases versus controls, the combination of growth/differentiation factor 15 (GDF-15, a cytokine regulating inflammatory pathways and cell repair and growth) and cystatin B (CSTB, an inhibitor of cathepsin L, possibly involved in vascular remodelling and atherogenesis) had the best diagnostic potential. As pointed in the accompanying commentary, probably there is no real need for circulating biomarkers for diagnostic purposes, because echography scan is a simple, powerful and reproducible tool which is also able to provide information about some morphological characteristics. However, circulating biomarkers may be helpful tool for prognostic purposes, in order to improve our current prediction of the growth rate, to aid in follow-up planning, and to select patients for surgery. The paper by Memon and colleagues represents a step forward, but further larger studies are needed to validate the effectiveness and cost-effectiveness of the use of circulating biomarkers in AAA.
Lomitapide in patients with homozygous familial hypercholesterolemia
Lomitapide is an oral inhibitor of the microsomal triglyceride transport protein (MTP), which is responsible for transferring triglycerides and phospholipids onto chylomicron and very low-density lipoprotein during their assembly in the intestine and the liver, respectively. Inhibiting MTP leads to reduced secretion of these lipoproteins into the circulation.
Homozygous familial hypercholesterolemia (HoFH) is a rare and life-threatening disease originally characterized clinically by plasma cholesterol levels >13 mmol/l (>500 mg/dl), extensive xanthomas, and marked premature and progressive atherosclerotic cardiovascular disease. Statins have proven efficacy as the mainstay of treatment in HoFH, and have been shown to reduce cardiovascular and all-cause mortality. However, only modest reductions in low-density lipoprotein cholesterol (LDL-C) plasma levels have been observed. 7 Here Kolovou et al. showed the efficacy of lomitapide in a small group of patients with HoFH (12 individuals). Daily lomitapide treatment with or without bi-weekly lipoprotein apheresis for 3-24 months decreased the median LDL-C level by 56.8% compared with lipid-lowering drugs alone and by 54% compared with lipid-lowering drugs plus lipoprotein apheresis (p ¼ 0.031). There was no alteration in the degree of fatty liver disease during the follow-up period, which was relatively short to detect alterations in long-standing steatosis. These data are in keeping with other recent evidences on the efficacy of lomitapide, but associated with disturbing side effects, that lead to drug discontinuation. 8 Thus, this drug can be considered in HoFH patients who are refractory to statins, ezetimibe and PCKS9 treatment (e.g. individuals who are homozygous because of null LDLR mutations).
However, the use of lomitapide is limited by its sideeffects and very high costs,
Physical activity and healthy microvascular ageing
Physical activity is known to regulate circulating cells, by increasing the number of endothelial progenitor cells and improving their function in clinical studies. 9 The mitochondrial adaptor p66Shc is a major source of ageing-induced generation of reactive oxygen species. Promoter DNA methylation inhibits p66Shc gene transcription. Here, Streese et al. in a cross-sectional study involving 158 individuals (38 healthy active, 36 healthy sedentary and 84 sedentary with >2 cardiovascular risk factors) showed that the level of physical activity was associated with the transcriptional control of redox protein p66Shc (the 66kD isoform of Shc adaptor proteins) in circulating peripheral blood mononuclear cells. In fact, healthy active subjects had blunted p66Shc expression. In contrast, hypomethylation of p66Shc promoter was observed in healthy sedentary and sedentary subjects with >2 cardiovascular risk factors, data not found in healthy active subjects. Thus, long-term physical activity improves vascular health in older adults. Reprogramming of DNA methylation on the p66Shc gene promoter may represent a putative mechanistic link whereby physical activity and fitness protect against age-related oxidative stress.
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